DcR3 在实体瘤中的预后价值：一项荟萃分析。
Prognostic value of DcR3 in solid tumors: A meta-analysis.
机构信息
Department of general surgery, Beijing Tongren hospital, Capital Medical University, Beijing, People's Republic of China.
Department of general surgery, Beijing Tongren hospital, Capital Medical University, Beijing, People's Republic of China.
出版信息
Clin Chim Acta. 2018 Jun;481:126-131. doi: 10.1016/j.cca.2018.02.038. Epub 2018 Feb 28.
BACKGROUND
Decoy receptor 3 (DcR3) has been reported to be overexpressed in a wide range of solid tumors, suggesting that DcR3 plays a crucial role in the development and progression of cancer. The present meta-analysis assesses the association between DcR3 expression and prognosis in patients with solid tumors.
METHODS
Eligible studies were identified by searching the PubMed, Web of Science, Cochrane Library, EMBASE, Chinese CNKI, and Wan Fang databases. The pooled hazard ratios (HRs) for overall survival (OS) and recurrence-free survival (RFS) were calculated using fixed effects models and random effects models, respectively.
RESULTS
Data from the 16 included studies, with 2209 patients, were reviewed and analyzed. DcR3 overexpression was significantly associated with worse OS in patients with solid tumors, but its expression might not be related to RFS in malignancies.
CONCLUSIONS
Current evidence demonstrates that increased DcR3 expression correlates with a poor prognosis in cancer patients, which suggests that the expression status of DcR3 is a useful biomarker for the prediction of prognosis in patients with solid tumors.
背景
诱饵受体 3（DcR3）在广泛的实体瘤中过度表达，表明 DcR3 在癌症的发生和发展中起着关键作用。本荟萃分析评估了 DcR3 表达与实体瘤患者预后之间的关系。
方法
通过检索 PubMed、Web of Science、Cochrane 图书馆、EMBASE、中国知网和万方数据库，确定了符合条件的研究。使用固定效应模型和随机效应模型分别计算总生存（OS）和无复发生存（RFS）的合并风险比（HR）。
结果
对 16 项纳入研究、2209 名患者的数据进行了回顾和分析。DcR3 过表达与实体瘤患者的 OS 较差显著相关，但在恶性肿瘤中，其表达与 RFS 可能无关。
结论
目前的证据表明，DcR3 表达增加与癌症患者的预后不良相关，这表明 DcR3 的表达状态是预测实体瘤患者预后的有用生物标志物。
Zotero 插件